Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia
Male
0301 basic medicine
Delayed Diagnosis
Adolescent
Interferon alpha-2
Antiviral Agents
Polyethylene Glycols
03 medical and health sciences
Ribavirin
Humans
Asymptomatic Infections
Aged
Aged, 80 and over
R
Interferon-alpha
Pneumonia
Middle Aged
Recombinant Proteins
3. Good health
Middle East Respiratory Syndrome Coronavirus
Medicine
Original Article
Drug Therapy, Combination
Female
Coronavirus Infections
Respiratory Insufficiency
DOI:
10.5144/0256-4947.2014.396
Publication Date:
2017-03-25T10:16:28Z
AUTHORS (14)
ABSTRACT
Middle Eastern respiratory syndrome caused by novel coronavirus (MERS CoV) has been a major public health challenge since it was first described in 2012 Saudi Arabia. So far, there is no effective treatment for this serious illness, which features high mortality rate. We report an initial experience of the use ribavirin and interferon (IFN)-a2b management MERS CoV at tertiary care hospital.A case series 6 patients admitted with confirmed diagnosis were treated IFN-a2b addition to supportive management. The patients' demographics, clinical parameters, outcomes recorded. Fifty-four close contacts these screened CoV.Six infection included study. Four cases featured symptomatic disease, including pneumonia failure, while 2 asymptomatic patients. reverse transcription-polymerase chain reaction detection consensus viral RNA targets upstream E gene (UPE) open reading frame (ORF1b) on sputum sample. comorbid conditions, time initiation treatment, recorded.Three out who had conditions died during study period, 3 suc.cessful outcomes. delayed average 15 days those died. Only 54 (3.7%) positive CoV.Treatment may be infected CoV. There appears low infectivity rate among
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (36)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....